[{"id":"4257f9d5-1726-4b59-9737-b7a9b738c651","acronym":"","url":"https://clinicaltrials.gov/study/NCT05892653","created_at":"2023-06-07T14:07:59.887Z","updated_at":"2024-07-02T16:35:42.214Z","phase":"Phase 1","brief_title":"A Study of ABM-1310 in Patients With BRAF V600-Mutant Relapsed and Drug Resistant Primary Malignant Brain Tumors","source_id_and_acronym":"NCT05892653","lead_sponsor":"ABM Therapeutics Shanghai Company Limited","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • BRAF positive","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • BRAF positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABM-1310"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 06/30/2023","start_date":" 06/30/2023","primary_txt":" Primary completion: 05/29/2028","primary_completion_date":" 05/29/2028","study_txt":" Completion: 05/29/2028","study_completion_date":" 05/29/2028","last_update_posted":"2023-07-24"},{"id":"3bf19aa7-554a-40df-9ef3-ee087e98a821","acronym":"","url":"https://clinicaltrials.gov/study/NCT05501912","created_at":"2022-08-16T12:57:46.458Z","updated_at":"2024-07-02T16:35:47.147Z","phase":"Phase 1","brief_title":"A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors","source_id_and_acronym":"NCT05501912","lead_sponsor":"ABM Therapeutics Shanghai Company Limited","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • BRAF positive","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • BRAF positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABM-1310"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 08/24/2025","primary_completion_date":" 08/24/2025","study_txt":" Completion: 08/24/2025","study_completion_date":" 08/24/2025","last_update_posted":"2023-05-25"}]